发明申请
US20100227869A1 ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
审中-公开
纯化喹啉吡啶吡啶并使用它作为NICOTINIC乙酰胆碱受体配体
- 专利标题： ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
- 专利标题（中）： 纯化喹啉吡啶吡啶并使用它作为NICOTINIC乙酰胆碱受体配体
-
申请号： US12160402申请日： 2007-02-13
-
公开(公告)号： US20100227869A1公开(公告)日： 2010-09-09
- 发明人: Dan Peters , Daniel B. Timmermann , Gunnar M. Olsen , Elsebet Østergaard Nielsen , Tino Dyhring
- 申请人： Dan Peters , Daniel B. Timmermann , Gunnar M. Olsen , Elsebet Østergaard Nielsen , Tino Dyhring
- 优先权： DKPA200600224 20060216
- 国际申请： PCT/EP2007/051399 WO 20070213
- 主分类号： A61K31/501
- IPC分类号： A61K31/501 ; C07D403/12 ; A61P25/00 ; A61P29/00 ; A61P1/00 ; A61P9/12 ; A61P15/00 ; A61P17/00
摘要：
This invention relates to novel enantiopure azabicyclo pyridazinyloxy derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.